Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very low or no dividends
About
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, reasonably priced on P/FC.
Target Price
The average target price of DVAX is 16 and suggests 3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation sug
Buy
Sell